A Randomised Trial Evaluating Continuous Subcutaneous Infusion of Formulations of NN1218 and NovoLog® in Subjects With Type 1 Diabetes

Inclusion Criteria:

- Type 1 diabetes mellitus (diagnosed clinically) for at least 12 months prior to the
screening visit (Visit 1)

- Treatment with the same insulin analogue by CSII (continuous subcutaneous insulin
infusion) for the previous 3 months prior to the screening visit (Visit 1)

- Using a MiniMed Paradigm® pump (515/715, 522/722 or 523/723) for the previous 6
months prior to the screening visit (Visit 1)

- Glycosylated haemoglobin (HbA1c) below or equal to 9.0% by central laboratory

- Body Mass Index (BMI) below or equal to 35.0 kg/m^2

Exclusion Criteria:

- History of diabetic ketoacidsosis (DKA) episodes requiring hospitalization within 6
months prior to the screening visit (Visit 1)

- History of abscess at the infusion site within 6 months prior to the screening visit
(Visit 1)

- Hypoglycaemic unawareness as judged by the Investigator or history of severe
hypoglycaemic episodes requiring hospitalization within the last 6 months prior to
the screening visit (Visit 1)